Jump to main content
Jump to site search

Issue 3, 2019
Previous Article Next Article

An improved automated radiosynthesis of [18F]FET-βAG-TOCA

Author affiliations


The fluorine-18 radiolabelled octreotide derivative [18F]FET-βAG-TOCA targeting somatostatin receptor type 2, has been evaluated clinically for positron emission tomography (PET) imaging of neuroendocrine tumours (NETs). We report an improved automated radiosynthesis of [18F]FET-βAG-TOCA with several advantages over the current automated GMP synthesis: 1) cartridge-based purification of 2-[18F]fluoroethylazide ([18F]FEA); 2) simple set-up for the radiolabelling on a single cassette; 3) HPLC purification using a biocompatible mobile phase. [18F]FET-βAG-TOCA was produced with a radiochemical yield of 16.7 ± 0.6% (non-decay corrected) and radiochemical purity ≥98%. The automated synthesis produced multi-patient doses (900 MBq) that were radiochemically stable (≥98%) over 4 hours. In addition, the automated procedure described can be used, with minimal adaptation, to radiolabel any alkyne-containing peptide with [18F]FEA using the GE FASTlab™ platform.

Graphical abstract: An improved automated radiosynthesis of [18F]FET-βAG-TOCA

Back to tab navigation

Supplementary files

Publication details

The article was received on 29 Oct 2018, accepted on 11 Dec 2018 and first published on 11 Dec 2018

Article type: Paper
DOI: 10.1039/C8RE00279G
React. Chem. Eng., 2019,4, 569-574

  •   Request permissions

    An improved automated radiosynthesis of [18F]FET-βAG-TOCA

    L. Allott, C. Barnes, D. Brickute and E. O. Aboagye, React. Chem. Eng., 2019, 4, 569
    DOI: 10.1039/C8RE00279G

Search articles by author